Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 362

1.

The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.

Eck MJ, Manley PW.

Curr Opin Cell Biol. 2009 Apr;21(2):288-95. doi: 10.1016/j.ceb.2009.01.014. Epub 2009 Feb 11. Review.

PMID:
19217274
[PubMed - indexed for MEDLINE]
2.

Imatinib: a selective tyrosine kinase inhibitor.

Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. Review.

PMID:
12528769
[PubMed - indexed for MEDLINE]
3.

Imatinib as a paradigm of targeted therapies.

Druker BJ.

Adv Cancer Res. 2004;91:1-30. Review.

PMID:
15327887
[PubMed - indexed for MEDLINE]
4.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
[PubMed - indexed for MEDLINE]
5.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.

Zámečníkova A.

Expert Rev Hematol. 2010 Feb;3(1):45-56. doi: 10.1586/ehm.09.66. Review.

PMID:
21082933
[PubMed - indexed for MEDLINE]
6.

Inhibitors of Bcr-abl... breaking new ground again.

Ohren JF, Sebolt-Leopold JS.

Nat Chem Biol. 2006 Feb;2(2):63-4. No abstract available.

PMID:
16421581
[PubMed - indexed for MEDLINE]
7.

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.

Lee TS, Potts SJ, Kantarjian H, Cortes J, Giles F, Albitar M.

Cancer. 2008 Apr 15;112(8):1744-53. doi: 10.1002/cncr.23355.

PMID:
18338744
[PubMed - indexed for MEDLINE]
Free Article
8.

Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.

Mol CD, Fabbro D, Hosfield DJ.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):639-48. Review.

PMID:
15503866
[PubMed - indexed for MEDLINE]
9.

Lessons learned from the development of imatinib.

Lydon NB, Druker BJ.

Leuk Res. 2004 May;28 Suppl 1:S29-38. Review. No abstract available.

PMID:
15036939
[PubMed - indexed for MEDLINE]
10.

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

Kim D, Kim DW, Cho BS, Goh HG, Kim SH, Kim WS, Lee J, Kweon IY, Park SH, Yoon JH, Kim ND, Chun H.

Leuk Res. 2009 Sep;33(9):1260-5. doi: 10.1016/j.leukres.2008.12.017. Epub 2009 Feb 6.

PMID:
19201023
[PubMed - indexed for MEDLINE]
11.

Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells.

Chang S, Yin SL, Wang J, Jing YK, Dong JH.

Molecules. 2009 Oct 19;14(10):4166-79. doi: 10.3390/molecules14104166.

PMID:
19924055
[PubMed - indexed for MEDLINE]
Free Article
12.

Structural biology contributions to tyrosine kinase drug discovery.

Cowan-Jacob SW, Möbitz H, Fabbro D.

Curr Opin Cell Biol. 2009 Apr;21(2):280-7. doi: 10.1016/j.ceb.2009.01.012. Epub 2009 Feb 7. Review.

PMID:
19208462
[PubMed - indexed for MEDLINE]
13.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2008 May;93(5):653-61. doi: 10.3324/haematol.12212. Epub 2008 Mar 26.

PMID:
18367480
[PubMed - indexed for MEDLINE]
Free Article
14.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Engelman JA, Settleman J.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5. Review.

PMID:
18325754
[PubMed - indexed for MEDLINE]
15.

Targeting tyrosine kinases in cancer: the second wave.

Baselga J.

Science. 2006 May 26;312(5777):1175-8.

PMID:
16728632
[PubMed - indexed for MEDLINE]
16.

Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB.

Biochemistry. 2010 May 4;49(17):3611-8. doi: 10.1021/bi100070r.

PMID:
20337484
[PubMed - indexed for MEDLINE]
17.

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.

Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1421-5. Epub 2005 Dec 5.

PMID:
16332440
[PubMed - indexed for MEDLINE]
18.

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G.

Curr Drug Targets. 2009 Jun;10(6):530-6. Review.

PMID:
19519355
[PubMed - indexed for MEDLINE]
19.

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

PMID:
19366808
[PubMed - indexed for MEDLINE]
Free Article
20.

[Kinase inhibitors].

Yamori T, Kong D.

Nihon Rinsho. 2010 Jun;68(6):1059-66. Review. Japanese.

PMID:
20535956
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk